PD31-10 DEMOGRAPHICS AND MANAGEMENT COSTS OF VHL PATIENTS WITH A PHEOCHROMOCYTOMA: A NATIONAL INPATIENT SERVICE ANALYSIS Timothy King*, Olubode Olufajo, Anish Jain, Ifeanyichukwu Okereke, Imazul Qadir, Tishina Tittley, Pamela Coleman, Adam Metwalli, Washington, DC INTRODUCTION AND OBJECTIVE: Von Hippel Lindau (VHL) is an autosomal dominant hereditary disorder characterized by multiple neoplastic lesions, including pheochromocytomas. This study retro- spectively reviewed a large inpatient database to describe the charac- teristics of VHL patients with pheochromocytoma who were managed with adrenalectomy during an inpatient stay. METHODS: Data from the National Inpatient Sample database (2005-2014) was used to identify patients who underwent an adrenal- ectomy on admission and were then stratified into VHL and non-VHL patient cohorts. Demographics, total hospital costs, and hospital characteristics were extracted. Differences were compared using descriptive statistics. RESULTS: There were 33,535 admissions of patients with a pheochromocytoma who had an adrenalectomy, with 243 [0.7%] also having the diagnosis of VHL. VHL patients on average were younger [28y vs. 54y, p<0.001] and more likely to be male [56% vs. 39%, p<0.05]. There were no significant differences in the race of patients with VHL compared to non-VHL patients. When examined for other comorbidities, VHL patients had lower rates of diabetes mellitus [41% vs. 24%, p<0.05], and hypertension [42% vs. 71%, p<0.001], but were more likely to have CNS neoplasms [4.1% vs. 0%, p<0.001]. However, VHL and non-VHL patients had similar rates of coronary artery disease [6.5% vs. 6.4%, p[0.92] and congestive heart failure [1.9% vs. 3.8%, p[0.48]. In regard to cost analysis, patients with VHL had an average length of stay of 7 days [95% CI: 2d e 12.2d] while non-VHL patients had an average stay of 4.4 days [95% CI: 4.2d-4.6d]. VHL patients had higher rates of private insurance [64% vs. 56%, p<0.001] and the overwhelming majority were treated in urban teaching hospitals [96% vs. 75% p[0.06], which approached statistical significance. Lastly, the average cost of the hospital stays trended greater in the VHL patients [$30,207, 95% CI: $2,646 e $57,767] compared to non-VHL patients [$14,281, 95% CI: $13,549- $15,012]. CONCLUSIONS: VHL patients with pheochromocytoma adre- nalectomies were younger, more likely to be male, had higher rates of CNS tumors, and were less likely to have diabetes and hypertension. The lengths of stay and hospital costs for VHL patients trend greater than the general population of patients that are admitted for resection of a pheochromocytoma. These data suggest the increased complexity of treating patients with VHL as well as demonstrate the significant cost of treating a pheochromocytoma in a single admission. Source of Funding: N/A PD31-11 CONDITIONAL PROBABILITY SURVIVAL ANALYSIS OF PATIENTS WITH MALIGNANT ADRENAL PHEOCHROMOCYTOMAS Wenjun Xiao*, Yu Zhu, Yao Zhu, Dingwei Ye, Shangai, China, People's Republic of INTRODUCTION AND OBJECTIVE: Malignant Pheochromo- cytoma (PHEO) may be commom malignant tumor of adrenal medulla. The disease may have different behavior stratified by different prog- nostic factors. Besides, disease prognosis is not constant over time; consequently, the conditional survival (CS) of patients with malignant PHEO needs to be evaluated. CS was defined as the probability of surviving for an additional period on the condition that a patient had already survived for a designated length of time. METHODS: The SEER database was queried for patients aged >18 years diagnosed with malignant PHEO between 2004 and 2015. Demographic, clinical and pathologic information included patient gender, age at diagnosis, race, year of diagnosis, surgery, laterality, clinical stage, metastasis at diagnosis and survival status as of December 31, 2016. Cases with more than one primary malignant tu- mors, or unavailable follow-up information were excluded. Survival analysis were performed. Conditional survival, CS(y/x), is the probability of surviving an additional y years, S(xþy), given that the patient has already survived x years, S(x). The mathematical definition of CS can be expressed as: CS(y/x)[S(xþy)/S(x). RESULTS: A total of 210 patients were selected, and 64 cases had metastatic disease at diagnosis. In univariate analysis, factors associated with lower overall survival (OS) included older age, diag- nosed with distant metastases,and failure to undergo any surgery. Cox proportional hazards regression analysis showed that these factors independently associated with higher overall mortality. These factors were also independently associated with cancer-specific survival (CSS). Patients diagnosed with metastatic disease had a poor prognosis with a median OS and CSS of 19 months, while patients with localized disease had a longer median OS of 131 months. During the first 5 years after their initial diagnosis, the 1-year CS of patients who had survived >24 months increased to approximately 90%, while OS decreased progressively from about 70%. The gains in 1-year CS over time were more pronounced in patients with poor prognostic factors. These differences in 1-year CS between the different prognostic factor groups decreased with time from diagnosis, or even disappeared. CONCLUSIONS: These findings provided a new perspective for understanding the prognosis of malignant PHEO. Source of Funding: no PD31-12 A COMPARISON OF INPATIENT ADMISSIONS FOR PHEOCHROMOCYTOMA IN MULTIPLE ENDOCRINE NEOPLASIA SYNDROME: A NATIONAL INPATIENT SAMPLE ANALYSIS Timothy King*, Olubode Olufajo, Anish Jain, Ifeanyichukwu Okereke, Imazul Qadir, Tishina Tittley, Pamela Coleman, Adam Metwalli, Washington, DC INTRODUCTION AND OBJECTIVE: Pheochromocytomas occur in approximately 40% of patients with Multiple Endocrine Neoplasia (MEN) Type 2 syndromes. This study retrospectively reviewed a large inpatient database to describe the demographic characteristics and hospital costs of MEN patients with a pheochro- mocytoma who were managed with adrenalectomy during an inpatient stay. METHODS: All recorded hospital admissions between 2005 and 2014 with a diagnosis of MEN and pheochromocytoma were identified in the National Inpatient Sample. MEN and non-MEN patients with pheochromocytomas were selected and admissions involving adrenalectomies were identified. Demographic data, comorbidities, total hospital cost, and hospital characteristics were determined. RESULTS: There were 33,535 patients with pheochromocy- tomas who underwent an adrenalectomy, of which 239 [0.8%] had MEN syndrome. Patients with MEN were younger [39.7 years, 95% CI: 35.6y- 43.8y] compared to non-MEN patients [53.6 years, 95% CI: 53.2y- 54.1y]. There were no significant differences in sex [38% male in MEN group vs 39% male in non-MEN group, p[0.82] or race of patients in both groups. MEN patients had lower rates of diabetes mellitus [6% vs. 24%, p<0.01], and hypertension [45% vs. 71%, p<0.001]. Both groups had similar rates of coronary artery disease [1.9% vs. 6.4%, p[0.20] and congestive heart failure [0% vs. 3.9%, p[0.48]. From a mortality standpoint, MEN patients were more likely to die during hospitalization compared to non-MEN patients [2.1% vs. 0.31%, p<0.05]. Patients with MEN had an average length of stay of 2.8 days [95% CI: 2.1d e 3.4d] while non-MEN patients had an average admission length of 4.4 days [95% CI: 4.2d-4.6d]. Both groups had similar rates of private insurance [72% for MEN vs. 56% for non-MEN, p[0.09], and were predominantly treated in urban e634 THE JOURNAL OF UROLOGY Ò Vol. 203, No. 4S, Supplement, Saturday, May 16, 2020 Copyright © 2020 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.